MedTrace Logo

177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

NCT01237457 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 143

Last updated 2023-03-20

No results posted yet for this study

Summary

This is a phase II treatment protocol evaluating 177Lu-DOTATATE therapy for somatostatin receptor-expressing cancers including, but not limited to, those arising from the neural crest and involving such organs as the lungs, breast, gastrointestinal tract, skin, and endocrine (examples: pheochromocytoma, medullary carcinoma of the thyroid, non-radioiodine avid differentiated thyroid cancer, melanoma, renal cell, Merkel cell, paraganglioma, small cell lung, Carcinoid, and pancreatic islet cell malignancies).

Conditions

Interventions

DRUG

177Lu-DOTATATE

Patients will receive 200mCi dose of 177Lu Dotatate

Sponsors & Collaborators

  • Excel Diagnostics and Nuclear Oncology Center

    collaborator OTHER

  • Ebrahim S Delpassand

    lead OTHER

Principal Investigators

  • Ebrahim S Delpassand, M.D · Excel Diagnostics and Nuclear Oncology Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-27
Primary Completion
2016-11-17
Completion
2017-07-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01237457 on ClinicalTrials.gov